Gilead to pay $11.9B for cancer treatment developer Kite


Gilead Sciences will pay US11.9 billion in cash to buy Kite Pharma and plant a stake in an emerging area of cancer treatments that train a patient's immune cells to attack tumors. Kite's portfolio of potential treatments includes one for some forms of the blood cancer lymphoma that could receive U.S. regulatory approval later this year.



from Biotech News